A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

被引：0
|
作者：
Roche Kapoor
Matthew P. Deek
Riley McIntyre
Natasha Raman
Megan Kummerlowe
Iyah Chen
Matt Gaver
Hao Wang
Sam Denmeade
Tamara Lotan
Channing Paller
Mark Markowski
Michael Carducci
Mario Eisenberger
Tomasz M. Beer
Daniel Y. Song
Theodore L. DeWeese
Jason W. Hearn
Stephen Greco
Curtiland DeVille
Neil B. Desai
Elisabeth I. Heath
Stanley Liauw
Daniel E. Spratt
Arthur Y. Hung
Emmanuel S. Antonarakis
Phuoc T. Tran
机构：
[1] Sidney Kimmel Comprehensive Cancer Center,Department of Radiation Oncology and Molecular Radiation Sciences
[2] Johns Hopkins Hospital,Department of Medical Oncology
[3] Sidney Kimmel Comprehensive Cancer Center,The James Buchanan Brady Urological Institute and Department of Urology
[4] Johns Hopkins Hospital,Department of Pathology
[5] Johns Hopkins University School of Medicine,OHSU Knight Cancer Institute
[6] Johns Hopkins University School of Medicine,Department of Radiation Oncology
[7] Oregon Health & Science University,Department of Radiation Oncology
[8] University of Michigan,Karmanos Cancer Institute, Department of Oncology
[9] University of Texas Southwestern Medical Center,Department of Radiation Oncology and Cellular Oncology
[10] Wayne State University School of Medicine,Department of Radiation Medicine
[11] University of Chicago,undefined
[12] OHSU Knight Cancer Institute,undefined
[13] Oregon Health & Science University,undefined
来源：
BMC Cancer | / 19卷
关键词：
Recurrent prostate cancer; Salvage radiation therapy (SRT); High-risk prostate cancer; Enzalutamide; Prostatectomy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)
    Kapoor, Roche
    Deek, Matthew P.
    McIntyre, Riley
    Raman, Natasha
    Kummerlowe, Megan
    Chen, Iyah
    Gaver, Matt
    Wang, Hao
    Denmeade, Sam
    Lotan, Tamara
    Paller, Channing
    Markowski, Mark
    Carducci, Michael
    Eisenberger, Mario
    Beer, Tomasz M.
    Song, Daniel Y.
    DeWeese, Theodore L.
    Hearn, Jason W.
    Greco, Stephen
    DeVille, Curtiland
    Desai, Neil B.
    Heath, Elisabeth I.
    Liauw, Stanley
    Spratt, Daniel E.
    Hung, Arthur Y.
    Antonarakis, Emmanuel S.
    Tran, Phuoc T.
    BMC CANCER, 2019, 19 (1)
  • [2] Phase II, double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial.
    Tran, Phuoc T.
    Lowe, Kathryn
    Wang, Hao
    Tsai, Hua-Ling
    Song, Daniel Y.
    Hung, Arthur
    Hearn, Jason W. D.
    Lotan, Tamara L.
    Paller, Channing Judith
    Markowski, Mark Christopher
    Denmeade, Samuel R.
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Orton, Matthew
    Deville, Curtiland
    Liauw, Stanley L.
    Heath, Elisabeth I.
    Desai, Neil B.
    Beer, Tomasz M.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Phase II Randomized Study of Salvage Radiation Therapy (SRT) plus Enzalutamide or Blinded Placebo for High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy: The SALV-ENZA Trial
    Tran, P. T.
    Lowe, K.
    Wang, H.
    Tsai, H. L.
    Song, D.
    Hung, A. Y.
    Hearn, J. W. D.
    Miller, S. R., II
    Lotan, T. L.
    DeWeese, T. L.
    Orton, M. D.
    Deville, C., Jr.
    Liauw, S.
    Heath, E.
    Greco, S. C.
    Desai, N. B.
    Spratt, D. E.
    Feng, F. Y.
    Beer, T.
    Antonarakis, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S37 - S37
  • [4] Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
    Tran, Phuoc T.
    Lowe, Kathryn
    Tsai, Hua-Ling
    Song, Daniel Y.
    Hung, Arthur Y.
    Hearn, Jason W. D.
    Miller, Steven
    Proudfoot, James A.
    Deek, Matthew P.
    Phillips, Ryan
    Lotan, Tamara
    Paller, Channing J.
    Marshall, Catherine H.
    Markowski, Mark
    Dipasquale, Shirl
    Denmeade, Samuel
    Carducci, Michael
    Eisenberger, Mario
    DeWeese, Theodore L.
    Orton, Matthew
    Deville, Curtiland
    Davicioni, Elai
    Liauw, Stanley L.
    Heath, Elisabeth I.
    Greco, Stephen
    Desai, Neil B.
    Spratt, Daniel E.
    Feng, Felix
    Wang, Hao
    Beer, Tomasz M.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1307 - +
  • [5] Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
    Rugo, Hope S.
    Stopeck, Alison T.
    Joy, Anil A.
    Chan, Stephen
    Verma, Shailendra
    Lluch, Anna
    Liau, Katherine F.
    Kim, Sinil
    Bycott, Paul
    Rosbrook, Brad
    Bair, Angel H.
    Soulieres, Denis
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2459 - 2465
  • [6] Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial
    Murtola, Teemu J.
    Syvala, Heimo
    Tolonen, Teemu
    Helminen, Mika
    Riikonen, Jarno
    Koskimaki, Juha
    Pakarainen, Tomi
    Kaipia, Antti
    Isotalo, Taina
    Kujala, Paula
    Tammela, Teuvo L. J.
    EUROPEAN UROLOGY, 2018, 74 (06) : 697 - 701
  • [7] Darolutamide plus androgen-deprivation therapy in patients with high-risk biochemical recurrence of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP)
    Chehrazi-Raffle, Alex
    Morgans, Alicia K.
    Gschwed, Jurgen E.
    Shore, Neal D.
    Ross, Ashley
    Feng, Felix Y.
    Hope, Thomas A.
    Nordquist, Luke
    Niazi, Tamim
    Trandafir, Lucia
    Le Berre, Marie-Aude
    Kuss, Iris
    Joensuu, Heikki
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC).
    Agarwal, Neeraj
    Azad, Arun
    Fizazi, Karim
    Mateo, Joaquin
    Matsubara, Nobuaki
    Shore, Neal D.
    Chakrabarti, Jayeta
    Chen, Hsiang-Chun
    Lanzalone, Silvana
    Niyazov, Alexander
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [9] A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer
    Horti, Jozsef
    Widmark, Anders
    Stenzl, Arnulf
    Federico, Miriam H.
    Abratt, Raymond P.
    Sanders, Nick
    Pover, Gillian M.
    Bodrogi, Istvan
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2009, 24 (02) : 175 - 180
  • [10] BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer.
    Mettu, Niharika B.
    Niedzwiecki, Donna
    Boland, Patrick Mckay
    Fakih, Marwan
    Arrowood, Christy
    Bolch, Emily
    Hurwitz, Herbert
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345